IT1260468B - Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole - Google Patents

Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole

Info

Publication number
IT1260468B
IT1260468B ITMI920162A ITMI920162A IT1260468B IT 1260468 B IT1260468 B IT 1260468B IT MI920162 A ITMI920162 A IT MI920162A IT MI920162 A ITMI920162 A IT MI920162A IT 1260468 B IT1260468 B IT 1260468B
Authority
IT
Italy
Prior art keywords
proteolytic enzymes
activity
polyethylenglycol
maintaining
enzymes modified
Prior art date
Application number
ITMI920162A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ITMI920162A priority Critical patent/IT1260468B/it
Publication of ITMI920162A0 publication Critical patent/ITMI920162A0/it
Priority to EP93914525A priority patent/EP0624191A1/en
Priority to US08/256,834 priority patent/US5514572A/en
Priority to AU34522/93A priority patent/AU665982B2/en
Priority to CA002129134A priority patent/CA2129134A1/en
Priority to JP5512940A priority patent/JPH07502900A/ja
Priority to PCT/EP1993/000205 priority patent/WO1993015189A1/en
Publication of ITMI920162A1 publication Critical patent/ITMI920162A1/it
Application granted granted Critical
Publication of IT1260468B publication Critical patent/IT1260468B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Viene descritto un procedimento che evita la perdita di attività enzimatica di enzimi proteolitici verso substrati macromolecolari quando, per aumentare le loro potenzialità applicative in campo biomedico o in biocatalisi, vengono modificati con polietilenglicole.
ITMI920162A 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole IT1260468B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITMI920162A IT1260468B (it) 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
EP93914525A EP0624191A1 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
US08/256,834 US5514572A (en) 1992-01-29 1993-01-29 Method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
AU34522/93A AU665982B2 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
CA002129134A CA2129134A1 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
JP5512940A JPH07502900A (ja) 1992-01-29 1993-01-29 ポリエチレングリコール変性タンパク分解酵素の活性を持続させる方法
PCT/EP1993/000205 WO1993015189A1 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920162A IT1260468B (it) 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole

Publications (3)

Publication Number Publication Date
ITMI920162A0 ITMI920162A0 (it) 1992-01-29
ITMI920162A1 ITMI920162A1 (it) 1993-07-29
IT1260468B true IT1260468B (it) 1996-04-09

Family

ID=11361713

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI920162A IT1260468B (it) 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole

Country Status (7)

Country Link
US (1) US5514572A (it)
EP (1) EP0624191A1 (it)
JP (1) JPH07502900A (it)
AU (1) AU665982B2 (it)
CA (1) CA2129134A1 (it)
IT (1) IT1260468B (it)
WO (1) WO1993015189A1 (it)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
AU697440B2 (en) * 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
WO1997024421A2 (en) * 1995-12-29 1997-07-10 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
AU5104098A (en) * 1996-11-14 1998-06-03 Polymer Technology Corporation Use of water soluble enzyme-polymer conjugates for cleaning contact lenses
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
BR9909130A (pt) 1998-03-26 2000-12-19 Procter & Gamble Variantes de protease de serina tendo substituições de amino-ácido
JP2002514411A (ja) * 1998-05-08 2002-05-21 ユニバーシティ オブ サザン カリフォルニア サイズ拡大型繊維素溶解酵素、及び繊維素溶解酵素のサイズ変更方法
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CA2376045A1 (en) 1999-07-22 2001-02-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
KR20020021397A (ko) 1999-07-22 2002-03-20 데이비드 엠 모이어 규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체
BR0012694A (pt) 1999-07-22 2002-04-09 Procter & Gamble Conjugado de protease, composição de limpeza e composição de tratamento pessoal
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
DE60223047T2 (de) 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal Verfahren zur herstellung von aktivierten polyethylenglykolen
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005011587A2 (en) * 2003-07-30 2005-02-10 New Century Pharmaceuticls Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US7338933B2 (en) 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
WO2006133088A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
CA2618878C (en) 2005-08-18 2016-06-28 Ambrx, Inc. Compositions of trna and uses thereof
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20070092925A1 (en) * 2005-10-25 2007-04-26 Conopco, Inc., D/B/A Unilever Method of treating skin by delivering specific protein stabilizers/protectors to skin proteins and methods of selecting said stabilizers
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
ES2457527T3 (es) 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
BRPI0717505B8 (pt) 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
ITRM20060682A1 (it) * 2006-12-19 2008-06-20 Sicit Chemitech S P A Nuovi derivati polimerici biodegradabili
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
NO2337846T3 (it) 2008-09-26 2018-06-16
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
DK2890402T3 (da) 2012-08-31 2019-07-15 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
MX2021002575A (es) 2018-09-11 2021-06-08 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
WO2020152713A1 (en) * 2019-01-25 2020-07-30 Council Of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4610879A (en) * 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5219995A (en) * 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification

Also Published As

Publication number Publication date
ITMI920162A0 (it) 1992-01-29
EP0624191A1 (en) 1994-11-17
WO1993015189A1 (en) 1993-08-05
AU665982B2 (en) 1996-01-25
CA2129134A1 (en) 1993-08-05
JPH07502900A (ja) 1995-03-30
US5514572A (en) 1996-05-07
AU3452293A (en) 1993-09-01
ITMI920162A1 (it) 1993-07-29

Similar Documents

Publication Publication Date Title
ATE256178T1 (de) Trichoderma cellulase mit hohem molekulargewicht
EP0813867A3 (en) Retroviral protease inhibitors
MC2313A1 (fr) Inhibiteurs d'enzymes
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
AU6328094A (en) Saccharin derivative proteolytic enzyme inhibitors
CA2070286A1 (en) Non Oxidative Ophthalmic Compositions and Methods for Preserving and Using Same
AU5485698A (en) Oxyiminopregnancarbolactone
ITMI920162A1 (it) Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
AU9737398A (en) Alpha-amylase mutants
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
BR0010220A (pt) Compostos de pirimidinona
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
GB9423970D0 (en) Oxidation
IT1251203B (it) Procedimento e apparecchiatura per la fermentazione di amminoacidi
AU6682594A (en) Treatment of septic shock
AU570574B2 (en) Depolymerase enzymes and treatment of fireblight
AU4714297A (en) Metalloproteinase inhibitors
DE59106876D1 (de) Verfahren zur enzymatischen Herstellung optisch aktiver Cyanhydrine.
UA26870C2 (uk) Спосіб підвищеhhя продукуваhhя протеїhу с, спосіб підвищеhhя рівhя його модифікації
AU7468894A (en) Process for the enzymatic preparation of optically active n-substituted-3-pyrrolidinol
FR2703692B1 (fr) Procede d'extraction de carotenouides et notamment d'astaxanthine a partir d'une culture de micro-algues.
AU5239290A (en) Purification of c.pseudotuberculosis toxin, and cloning and expression of toxin gene
EP0814661A4 (en) UBIQUITIN-CONJUGATED ENZYMS 7, 8 AND 9
FR2649719B1 (fr) Procede de protection et de conservation de micro-organismes notamment de bacteries
FR2705687B1 (fr) Identification clonage et expression de l'enzyme malolactique.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960130